Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gene therapy -- Ignore unavailable to you. Want to Upgrade?

To: Jongmans who wrote (95)	7/16/1999 8:49:00 AM
From: Jongmans	Read Replies (1) \| Respond to of 319

Genomes and Gene Therapy ASGT president ponders each field's effect on the other. The Scientist: the-scientist.library.upenn.edu Martin

To: Jongmans who wrote (95)	7/16/1999 12:15:00 PM
From: Mike McFarland	Respond to of 319

Great find Martin: SNP value hinges on the assumption that a finite number of common DNA variants in the human population make a significant contribution to genetic risk for common diseases, a hypothesis called common disease-common variant (CD-CV). Although unproven, the CD-CV hypothesis has held true in several cases, perhaps most notably in the case of the ApoE4 allele and its association with Alzheimer's disease. That was the jargon I needed to speed me on my way; CD-CV. I want to find a book, or surf around in the journals, and guage which diseases are tied to the snips, and which are too complex to be associated with just a few genes (oops, proteomics--a few genes is already very complicated). Boy, you sure would like to know which diseases are more likely to be cured by intervening at the genetic level-- whether it be with traditional gene therapy--adding functional genes, or with antisense ODNs, or by intervening in other pathways--signal transduction. I know that I'm only looking at a small part of biotech (for instance, I don't follow the MAb companies) but if you were going to follow just one sector of the economy for the next forty years, gene therapy is it. It will probably take me forty years to understand it! A shame my local library is so poorly stocked, I was reading through book reviews last night--I'd like to quit my job and become a professional student: One of those dudes who audits, never has to take the tests. What a life that would be, at least for a few years. If you come across a pharmacogenomics/'systems biology' reading list, show me the pointer. If I find any good reviews at amazon.com, I'll drop them off here as well. Also, check out my post on the Yahoo aria thread-- and tell me if you find any Genovo stuff... eeek: Somebody dropped off the url just now genovo.com Genovo's other partner is Biogen...cant be too happy about that. Sure hope Gilman does not hold a grudge against his boss...I feel queasy.